Cancer Biospecimen Acquisition and Biorepository

AECC癌症生物标本采集和生物储存资源（CBABR）的目标是提供一个符合NCI最佳实践的集中单位，用于癌症研究的高质量生物标本。CBABR负责监督AECC和其他研究者从实体瘤和血液肿瘤中获取恶性、良性、病变和未受累（正常）组织。CBABR是通过将多个联合癌症相关机构生物库合并为一个有凝聚力的癌症定向组织采集和储存生物库（作为前瞻性样本采集的核心）来组织的。CBABR是AECC，Einstein CTSA和其他NIH资助的中心在爱因斯坦的共同努力，并得到了几个机构倡议的支持，包括爱因斯坦的临床合作伙伴Montefiore医疗中心使用的普遍选择同意过程，与Montefiore手术病理学合作的组织采集专用人员，临床研究信息学支持将样本与医疗和研究记录联系起来，以及采用最先进的节能冷冻技术的专用安全存储空间。已经开发了一个基于网络的应用程序，允许研究人员确定CBABR中是否存在具有必要表型特征的组织。CBABR的重点是头颈癌、乳腺癌、结肠癌、肺癌、宫颈癌和卵巢癌、神经内分泌肿瘤和血液肿瘤。该中心目前存放了67，704份样本，包括自2011年底设立新的CBABR以来收集的5，704份样本，所有这些样本均可供调查人员使用。CBABR过程包括患者在初始癌症评估时的知情同意，计划的普遍“选择加入” 同意程序，注释到生物标本上的患者医疗和健康信息， 标本采集、处理和储存的集中管理，以及多层次的安全和 通过母公司CTSA生物储存库保护资源，包括24/7监控和报警 冗余备份。已经成立了一个CBABR科学审查委员会（SRB），以评估科学和 向AECC方案审查报告的生物标本使用申请的技术优点， 监查委员会（PRMC）批准并在必要时优先考虑拟议的组织使用。 还建立了要求外部调查人员合作的机制。一个 机构倡议将跟踪知情同意过程，并对贡献者进行后续查询， CBSR评估患者知识和满意度。

The goal of the AECC Cancer Biospecimen Acquisition and Biorepository Resource (CBABR) is to provide a centralized unit that meets the best practices of the NCI for high quality biospecimens for cancer research. The CBABR oversees the procurement of malignant, benign, diseased and uninvolved (normal) tissues from both solid and hematological tumors for use by AECC and other investigators. The CBABR has been organized through the consolidation of multiple federated cancer associated Institutional biobanks into a cohesive cancer oriented tissue acquisition and storage biobank that is the nucleus for prospective sample collection. The CBABR is a joint effort of AECC, the Einstein CTSA and other NIH funded centers at Einstein and is supported by several Institutional initiatives including a universal opt-in consent process in use by Einstein's clinical partner, Montefiore Medical Center, dedicated staffing for tissue acquisition in cooperation with Montefiore Surgical Pathology, Clinical Research Informatics support linking samples to medical and research records, and dedicated secure storage space utilizing the most advanced energy efficient freezer technology. A web-based application has been developed that allows investigators to determine if tissue exists in the CBABR with necessary phenotypic characteristics for their studies. The CBABR focus has been on head and neck cancer, breast, colon, lung, cervical and ovarian, neuroendocrine tumors, and hematological tumors. It currently houses 67,704 samples, including 5,704 samples collected since the institution of the new CBABR in late 2011, all of which are available for use by investigators. The CBABR process encompasses patient informed consent at initial cancer evaluation, planned universal "opt-in" consent procedures, patient medical and health information that is annotated to the biospecimens, centralized management of specimen collection, processing and storage, and multiple levels of security and protection of the resource through the parent CTSA biorepository including 24/7 monitoring and alarmed redundant backups. A CBABR Scientific Review Board (SRB) has been constituted to evaluate scientific and technical merit of applications for use of biospecimens that reports to the AECC Protocol Review and Monitoring Committee (PRMC) to approve and, when necessary, prioritize proposed tissue usage. Mechanisms for requested collaborations from outside investigators have been established as well. An institutional initiative will track the informed consent process and perform follow up queries on contributors to the CBSR to assess patient knowledge and satisfaction.